| Identification | Back Directory | [Name]
D-Phenylalanine, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-, methyl ester | [CAS]
13122-87-7 | [Synonyms]
D-Phenylalanine, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-, methyl ester | [Molecular Formula]
C27H28N2O5 | [MOL File]
13122-87-7.mol | [Molecular Weight]
460.52 |
| Hazard Information | Back Directory | [Description]
GSK-256066 is a PDE4 inhibitor. | [in vitro]
GSK256066 potently inhibited PDE4B enzymatic activity at sub-picomolar EC50 as previously reported._x000D_
_x000D_
Reference: Mol Ther. 2016 Dec;24(12):2078-2089. https://pubmed.ncbi.nlm.nih.gov/27731313/ | [in vivo]
When administered intratracheally to rats, GSK256066 inhibited LPS-induced pulmonary neutrophilia with ED(50) values of 1.1 μg/kg (aqueous suspension) and 2.9 μg/kg (dry powder formulation) and was more potent than an aqueous suspension of the corticosteroid fluticasone propionate (ED(50) 9.3 μg/kg)._x000D_
_x000D_
Reference: J Pharmacol Exp Ther. 2011 Apr;337(1):145-54. https://pubmed.ncbi.nlm.nih.gov/21205923/ | [target]
GSK-256066 is a PDE4 inhibitor. |
|
|